QUÉBEC CITY, March 15 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that its Senior Director, Head of Preclinical Development, Michael Teifel, Ph.D., will present preclinical results for PI3K/Erk inhibitors AEZS-129, AEZS-131, and AEZS-132, which support further evaluation as potential anticancer compounds. This oral presentation will be made during the Informa Life Sciences Protein Kinases Congress to be held March 22-23, 2011 in Berlin, Germany.
Title: | “Finding novel Kinases targets in oncology at Aeterna Zentaris - Development of inhibitors targeting the MAPK and PI3K pathways” |
| Presenter: | Michael Teifel, Ph.D., Senior Director, Head of Preclinical Development, Aeterna Zentaris |
| Date: | Tuesday, March 22, 2011 at 9:30 a.m. (local time) |
| Location: | Maritim ProArte Hotel, Berlin, Germany. |
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.